Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
autologous hematopoietic stem cells (3 trials)
busulfan (Myleran) (2 trials)
carboplatin (paraplatin) (2 trials)
cyclophosphamide (cytoxan) (4 trials)
cytarabine (cytosar-u) (1 trial)
dactinomycin (cosmegen) (3 trials)
doxorubicin (Doxil) (5 trials)
etoposide (vepesid) (5 trials)
ifosfamide (ifex) (2 trials)
melphalan (alkeran) (2 trials)
naltrexone (revia) (1 trial)
prednisone (meticorten) (1 trial)
sargramostim (leukine) (3 trials)
urea (1 trial)
vincristine (oncovin) (5 trials)
cisplatin (platinol) (1 trial)
epirubicin (ellence) (1 trial)
Intestinal Neoplasms (Phase 2)
Kidney Neoplasms (Phase 3)
Leukemia (Phase 3)
Lymphoma (Phase 3)
Neuroblastoma (Phase 2)
Rhabdomyosarcoma (Phase 2)
Sarcoma (Phase 3)
Wilms Tumor (Phase 3)
Trials (5 total)
Trial APIs (17 total)
